文献速递肥胖与代谢综合征糖尿病

代谢表型与心脏结构及临床结局的关联:英国生物银行研究

Associations of Metabolic Phenotypes with Cardiac Structure and Clinical Outcomes: Insights from the UK Biobank.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

结果显示不健康表型增加主要不良心血管事件风险,所有表型均增加全因死亡风险,且各表型呈现不同的心脏结构改变。

要点

  • 不健康表型(MUN和MUO)与主要不良心血管事件风险增加独立相关。
  • 所有代谢表型(MHO、MUN、MUO)均与全因死亡风险增加相关。
  • MUO表型显示左室射血分数降低,肥胖表型左室舒张末期容积增加。

核心结论

  • 代谢表型呈现不同的心脏结构改变和死亡风险增加,支持其用于心血管风险分层。

主要发现

  • 肥胖表型LVEDV增加(MHO β=4.67,MUO β=5.14),MUN的LVEDV降低(β=-1.25)。
  • MUN和MUO的MACE风险增加(aHR分别为1.55和1.95)。
  • MHO、MUN、MUO的全因死亡风险均增加(aHR分别为1.65、1.41、2.10)。

临床怎么用

  • 临床可依据肥胖和代谢状态对患者进行心血管风险分层,不健康表型需更积极干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Metabolic syndrome and obesity represent major cardiovascular risk factors, yet their combined effects on cardiac structure and clinical outcomes remain incompletely understood. OBJECTIVE: To examine associations between metabolic phenotypes, cardiac magnetic resonance imaging (CMR), and clinical outcomes. DESIGN: Prospective study with a median 5.1-year follow-up. SETTING: Population-based cohort from the UK Biobank. PARTICIPANTS: A total of 22 789 participants (mean age 64.1 ± 7.5 years, 52.6% female) were categorized as metabolically healthy nonobese (MHN) vs obese (MHO) or unhealthy nonobese (MUN) vs obese (MUO), based on obesity (body mass index ≥30 kg/m²) and metabolic status (prevalent diabetes or both hypertension and hyperlipidemia). MAIN OUTCOME MEASURE(S): Primary and secondary endpoints were major adverse cardiovascular events (MACE) and all-cause mortality, respectively. CMR included left ventricular ejection fraction (LVEF, %), end-diastolic volume (LVEDV, mL), myocardial mass (g), wall thickness (mm), cardiac output (L/min), and left atrial volume (mL). Linear regression and Cox proportional hazards models, adjusted for age, sex, and smoking, assessed associations between metabolic phenotypes, CMR, and clinical outcomes. RESULTS: In adjusted models, all phenotypes demonstrated increased WT (MHO: β=.53 [.50, .55]; MUN: β=.24 [.21, .27]; MUO: β=.66 [.61, .70]), compared to MHN. LVEDV was increased in obesity phenotypes (MHO: β=4.67 [4.07, 5.27]; MUO: β=5.14 [4.05, 6.22]) and decreased in MUN (β=-1.25 [-1.95, -.55]), while MUO showed reduced LVEF (β=-.48 [-.91, -.04]). MACE risk was increased in unhealthy phenotypes (MUN: adjusted hazard ratio (aHR) = 1.55 [1.16-2.07]; MUO: aHR = 1.95 [1.28-2.97]). All phenotypes showed increased all-cause mortality risk (MHO: aHR = 1.65 [1.23-2.21]; MUN: aHR = 1.41 [1.05-1.90]; MUO: 2.10 [1.41-3.15]). CONCLUSION: Metabolic phenotypes show distinct cardiac structural changes and increased mortality risk, supporting their potential in cardiovascular risk stratification.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Bogner B, Jung M, Reisert M, et al. Associations of Metabolic Phenotypes with Cardiac Structure and Clinical Outcomes: Insights from the UK Biobank. J Clin Endocrinol Metab. 2026. PMID: 41428372. doi:10.1210/clinem/dgaf684

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。